Dose-confirmatory Bridging Study in Total Hip Replacement

NCT01205932 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: Rivaroxaban (BAY59-7939)
DRUG: Rivaroxaban (BAY59-7939)
DRUG: Rivaroxaban (BAY59-7939)
DRUG: Enoxaparin

Sponsor

Bayer

Collaborators

[object Object]